03.11.20
A Note from the CEO
2019 was an extraordinary year for Ocular Science and our affiliates OSRX and Regenerative Science. We exceeded revenue and commercial goals across the board, thanks largely to an unprecedented surge of growth from OSRX, our 503A ophthalmic compounding pharmacy, which formulates 14 combinations of medications for post-op cataract and LASIK treatment, glaucoma management, myopia control, and soon, presbyopia.